Senator Mark Warner, a prominent figure on the Senate Select Committee on Intelligence, has expressed concerns regarding the potential risks posed by the Chinese company BGI, which he believes may surpass Huawei in significance. Speaking at the CNBC CFO Council Summit, Warner highlighted BGI's rapid growth in the genomics sector as a source of possible national security threats. Unlike Huawei, which focuses on telecommunications, BGI is involved in DNA collection and genomic research, operating labs across several countries.
BGI, originally the Beijing Genomics Institute, has evolved into one of the world's largest genomics companies, providing services such as DNA sequencing and genetic analysis for various organizations globally. U.S. intelligence officials indicate that BGI's extensive data collection capabilities could lead to a "DNA arms race," as genetic profiles can reveal sensitive information, including health risks and ancestry.
Warner raised alarms about BGI's connections to the Chinese Communist Party and military, suggesting that the company could leverage genetic data for surveillance and other strategic purposes. He drew parallels between BGI's ascent and Huawei's past, emphasizing the need for vigilance as the U.S. has already faced challenges in countering Huawei's influence in the telecommunications space.
Additionally, Warner criticized the U.S. intelligence community for its slow response to threats in the biotech sector, arguing for a more proactive approach that encompasses commercial technology. He also noted the importance of maintaining strong alliances with international partners to effectively track and respond to China's technological advancements. Warner's remarks underscore the complexities of U.S.-China relations in the context of emerging technologies and the imperative for the U.S. to regain its leadership in global standards-setting.